In research models, Retatrutide acts as a triple agonist of GLP-1, GIP, and glucagon receptors. This multi-pathway activation is studied for its potential to enhance glucose-dependent insulin secretion, promote satiety, slow gastric emptying, increase energy expenditure, and stimulate lipolysis and hepatic fat oxidation. It is primarily researched for its effects on metabolic regulation, body composition, appetite control, and lipid metabolism.

Chemical Structure: Retatrutide (LY3437943) is a synthetic 39-amino acid peptide based on a GIP backbone. It includes strategic amino acid substitutions (including α-aminoisobutyric acid) and a C20 fatty diacid chain attached for albumin binding, which significantly extends its half-life.